Differential vitamin D 24-hydroxylase/CYP24A1 gene promoter methylation in endothelium from benign and malignant human prostate

Epigenetic alterations occur in tumor-associated vessels in the tumor microenvironment. Methylation of the CYP24A1 gene promoter differs in endothelial cells isolated from tumors and non-tumor microenvironments in mice. The epigenetic makeup of endothelial cells of human tumor-associated vasculature is unknown due to difficulty of isolating endothelial cells populations from a heterogeneous tissue microenvironment. To ascertain CYP24A1 promoter methylation in tumor-associated endothelium, we utilized laser microdissection guided by CD31 immunohistochemistry to procure endothelial cells from human prostate tumor specimens. Prostate tissues were obtained following robotic radical prostatectomy from men with clinically localized prostate cancer. Adjacent histologically benign prostate tissues were used to compare endothelium from benign versus tumor microenvironments. Sodium bisulfite sequencing of CYP24A1 promoter region showed that the average CYP24A1 promoter methylation in the endothelium was 20% from the tumor microenvironment compared with 8.2% in the benign microenvironment (p<0.05). A 2-fold to 17-fold increase in CYP24A1 promoter methylation was observed in the prostate tumor endothelium compared with the matched benign prostate endothelium in four patient samples, while CYP24A1 remained unchanged in two patient sample. In addition, there is no correlation of the level of CYP24A1 promoter methylation in prostate tumor-associated endothelium with that of epithelium/stroma. This study demonstrates that the CYP24A1 promoter is methylated in tumor-associated endothelium, indicating that epigenetic alterations in CYP24A1 may play a role in determining the phenotype of tumor-associated vasculature in the prostate tumor microenvironment.

[1]  C. Matouk,et al.  Epigenetics of the vascular endothelium. , 2010, Journal of applied physiology.

[2]  C. Morrison,et al.  Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. , 2010, Cancer research.

[3]  E. Jaffe,et al.  Immunoguided laser assisted microdissection techniques for DNA methylation analysis of archival tissue specimens. , 2010, The Journal of molecular diagnostics : JMD.

[4]  Yong Li,et al.  Angiogenesis as a strategic target for prostate cancer therapy , 2010, Medicinal research reviews.

[5]  M. Klagsbrun,et al.  Cytogenetic abnormalities of tumor-associated endothelial cells in human malignant tumors. , 2009, The American journal of pathology.

[6]  T. Down,et al.  Placenta-specific Methylation of the Vitamin D 24-Hydroxylase Gene , 2009, Journal of Biological Chemistry.

[7]  C. Morrison,et al.  Central quadrant procurement of radical prostatectomy specimens , 2009, The Prostate.

[8]  I. Jo,et al.  Differential expression of stromal cell-derived factor 1 in human brain microvascular endothelial cells and pericytes involves histone modifications. , 2009, Biochemical and biophysical research communications.

[9]  D. Trump,et al.  Vitamin D signalling pathways in cancer: potential for anticancer therapeutics , 2007, Nature Reviews Cancer.

[10]  J. Herman,et al.  Identification of epigenetically silenced genes in tumor endothelial cells. , 2007, Cancer research.

[11]  N. Nowak,et al.  Epigenetic Silencing of CYP24 in Tumor-derived Endothelial Cells Contributes to Selective Growth Inhibition by Calcitriol* , 2007, Journal of Biological Chemistry.

[12]  J. Gillespie,et al.  Identification of a unique epigenetic sub‐microenvironment in prostate cancer , 2007, The Journal of pathology.

[13]  M. O. oude Egbrink,et al.  Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. , 2006, Cancer research.

[14]  Jorge Yao,et al.  1 a , 25-dihydroxyvitamin D 3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis , 2006 .

[15]  Wei-dong Yu,et al.  Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. , 2006, Cancer research.

[16]  E. Petricoin,et al.  Laser Capture Microdissection , 1996, Science.

[17]  L. Liotta,et al.  Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment , 2006, Cancer biology & therapy.

[18]  Yan Liu,et al.  Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. , 2006, Journal of the National Cancer Institute.

[19]  J. Gillespie,et al.  Tumor-associated endothelial cells display GSTP1 and RARβ2 promoter methylation in human prostate cancer , 2006, Journal of Translational Medicine.

[20]  J. Gillespie,et al.  Gene promoter methylation in prostate tumor-associated stromal cells. , 2006, Journal of the National Cancer Institute.

[21]  Peter Carmeliet,et al.  Angiogenesis in life, disease and medicine , 2005, Nature.

[22]  J. Pachter,et al.  Selective capture of endothelial and perivascular cells from brain microvessels using laser capture microdissection. , 2005, Brain research. Brain research protocols.

[23]  Jun Yao,et al.  Distinct epigenetic changes in the stromal cells of breast cancers , 2005, Nature Genetics.

[24]  E. Hurt,et al.  Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. , 2005, Cancer research.

[25]  H. Cross,et al.  Epigenetic regulation of Vitamin D hydroxylase expression and activity in normal and malignant human prostate cells , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[26]  Glenville Jones,et al.  Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. , 2005, Endocrinology.

[27]  D. McDonald,et al.  Cellular abnormalities of blood vessels as targets in cancer. , 2005, Current opinion in genetics & development.

[28]  J. Fish,et al.  Endothelial nitric oxide synthase: insight into cell-specific gene regulation in the vascular endothelium , 2005, Cellular and Molecular Life Sciences CMLS.

[29]  I. Leav,et al.  Dynamic regulation of estrogen receptor-beta expression by DNA methylation during prostate cancer development and metastasis. , 2004, The American journal of pathology.

[30]  P. du Souich,et al.  Effect of hypoxia on cytochrome P450 activity and expression. , 2004, Current drug metabolism.

[31]  Takaaki Masuda,et al.  Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  T. Shinki,et al.  Characterization of transgenic rats constitutively expressing vitamin D-24-hydroxylase gene. , 2002, Biochemical and biophysical research communications.

[33]  H. Cross,et al.  25-hydroxy-vitamin d metabolism in human colon cancer cells during tumor progression. , 2001, Biochemical and biophysical research communications.

[34]  B. May,et al.  Overview of regulatory cytochrome P450 enzymes of the vitamin D pathway , 2001, Steroids.

[35]  K. Kinzler,et al.  Genes expressed in human tumor endothelium. , 2000, Science.

[36]  W. Kuo,et al.  Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene , 2000, Nature Genetics.

[37]  R K Jain,et al.  Openings between defective endothelial cells explain tumor vessel leakiness. , 2000, The American journal of pathology.

[38]  R. Star,et al.  Analysis of segmental renal gene expression by laser capture microdissection. , 2000, Kidney international.

[39]  C. Kovacs,et al.  Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation. , 1997, Endocrine reviews.

[40]  F. Glorieux,et al.  In vitro metabolism of 25-hydroxycholecalciferol by isolated cells from human decidua. , 1985, The Journal of clinical endocrinology and metabolism.